Novo Nordisk Foundation
Challenge Programme 2027 – Advancing Next Generation AMR Diagnostics for Lower Respiratory Tract Infections
2-stage process: Stage 1 expression of interest, then shortlisted applicants invited to Stage 2 full proposal. Specific deadlines not stated in this segment.
Last updated:
No deadline is on file for this call. Check Novo Nordisk Foundation's own call page for the current round's status before you plan around it.
The Novo Nordisk Foundation Challenge Programme 2027 funds early-stage diagnostic innovation for lower respiratory tract infections with grants of €4-10 million over six years. Applicants must form consortiums of 2-4 research groups with at least one Danish institution and a main applicant at a European university or non-profit with tenured or tenure-track status. The call prioritises rapid, minimally invasive, affordable point-of-care diagnostics grounded in proof-of-concept research, and runs as a one-off competitive round.
Details
| Funder | Novo Nordisk Foundation |
| Budget | DKK 30–75 million (ca. EUR 4–10 million) |
| Duration | 6 years |
| Consortium | Required — consortium of 2-4 research groups (main applicant plus 1-3 co-applicants) |
| Application | 2-stage: Stage 1 expression of interest → Stage 2 full proposal with detailed budget and panel presentation |
| TRL | 1-3 |
| Frequency | Annual |
| Eligible countries | DK |
Recently updated
catalog cleanup 2026-07-04: duplicate row (canonical sibling kept)
Eligibility & scope
Supports early-stage proof-of-concept research for rapid, minimally invasive point-of-care diagnostics for antibiotic-resistant lower respiratory tract infections. Main applicant must be an independent tenured/tenure-track researcher at a European (EU, Schengen plus UK) university, hospital or non-profit; at least one applicant must be based in Denmark; for-profit product development is out of scope.
Who Should Apply
- •Tenured or tenure-track researchers at European universities, hospitals, or non-profit institutions with ≥75% employment
- •Consortium leaders assembling 2-4 research groups with at least one partner ≥75% employed at a Danish institution
- •Early-stage diagnostic research teams working on minimally invasive, affordable LRTI point-of-care tests
- •Groups with clinical translation potential but not seeking commercial product development funding
- •Applicants willing to engage industry partners as collaborators (not as funded co-applicants)
Key Dates
- •Two-stage process: Stage 1 expression of interest, followed by Stage 2 full proposal for shortlisted consortiums
- •Specific deadlines not yet published; check Novo Nordisk Foundation website for 2027 schedule
- •Six-year project duration if funded
Tips for Applicants
- ✓Consortium composition is gating: ensure your Danish partner meets the ≥75% employment threshold before submission, as misalignment here will stall Stage 1 review.
- ✓Stage 1 is a filter for fit and feasibility; spend it demonstrating clear proof-of-concept groundwork and naming committed co-applicants rather than speculating on final protocols.
- ✓Emphasise affordable, point-of-care delivery in your diagnostic design; Novo Nordisk Foundation prioritises implementation potential in lower-resource settings, not laboratory-only assays.
Frequently Asked Questions
How much can I receive from the Novo Nordisk Foundation Challenge 2027 AMR Diagnostics call?
Individual grants range from €4 million to €10 million (approximately DKK 30-75 million) for a six-year project. The total funding pool across all awards is approximately €20 million.
Do I need a consortium to apply?
Yes, you must assemble a consortium of 2-4 research groups, with yourself as the main applicant at a European tenured/tenure-track post and at least one co-applicant ≥75% employed at a Danish institution.
Can for-profit companies or industry partners receive funding?
No, for-profit product development is ineligible. However, industry partners may collaborate and contribute in-kind or as partners, provided they do not receive direct grant funding.
What type of diagnostics research is in scope?
Early-stage proof-of-concept research on rapid, minimally invasive, affordable point-of-care diagnostics for lower respiratory tract infections, anchored at a research institution or non-profit.
Is this a recurring call?
No, the Challenge Programme 2027 is a one-off call. There is no indication of future rounds at this time.
Related on Grantsby
- Novo Nordisk Foundation Challenge Programme, full programme guide
Eligibility, budget, success rates, application timeline, FAQ.
- Novo Nordisk Foundation Challenge Programme past winners & funded projects
Recent recipients, host institutions, and funded project titles. See who tends to win before you apply.
Summary generated by AI based on published grant information. Always verify details on the funder's website.
Similar grants
Challenge Programme
Novo Nordisk FoundationDeadline: 7 Oct 2026DKK 30-75 million per grantChallenge Programme 2027 – Advancing Next Generation AMR Diagnostics for Lower Respiratory Tract Infections
Novo Nordisk FoundationDeadline: 7 Oct 2026DKK 30-75 million per grantTandem Programme – Translational research collaboration between Basic and Clinical Researchers
Novo Nordisk FoundationDeadline: 21 Jan 2027Up to DKK 13M per grantOHAMR Research Call on New Treatments to Tackle AMR
SNSFJpi Amr
SNSF
Browse Related
Could Challenge Programme 2027 – Advancing Next Generation AMR Diagnostics for Lower Respiratory Tract Infections be right for you?
See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.
See my matches free →